UDI, QR Codes and Electronic Labelling under Nigerian Device Rules
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nigeria’s position on UDI and electronic labelling can be summarised as permitted at the rules layer, required at the GMP layer. The two layers use different verbs, and understanding the difference is what turns a confusing pair of provisions into a clear compliance design.
Rules layer (permitted) — the labelling rules on product identification provide:
- Devices, IVDs and related products must carry a product-specific identification, selectable from 7 forms: batch number, lot number, batch code, lot code, serial number, control number or version number (as applicable);
- The identification must be shown on all packaging components; where it cannot all be shown for reasons of size, the details should be shown on the primary packaging;
- Internationally recognised symbols, the Unique Device Identification (UDI), QR codes and electronic labelling may be used.
GMP layer (required) — DER-GDL-025-00 §12.6: devices must have a UDI to enhance traceability, and the UDI must be indicated on the packaging.
The combined practical conclusion of these 2 provisions: UDI is not optional in Nigeria; QR codes and electronic labelling are expressly permitted supplementary means. Note the asymmetry in tone: for QR codes and electronic labels the rules layer says a company may use them if it wishes, while for UDI the GMP guideline uses mandatory language. A packaging design that treats both as equally optional would fail a GMP inspection even if it passed artwork review, which is why the distinction must be understood at design time rather than discovered at inspection time.
2. Legal basis
| Instrument | Reference number | Date | Provisions |
|---|---|---|---|
| NAFDAC Labelling Rules for Medical Devices, IVDs and Related Products (labelling rules) | Labelling Rules 2024 | 2024 | Product identification provision (paragraphs 1–3: product-specific identification, display level, international symbols / UDI / QR / electronic labelling) |
| NAFDAC Good Manufacturing Practice (GMP) for Medical Devices, IVDs and Related Products Guidelines 2024 | DER-GDL-025-00 | Effective 11 November 2024 | §12.6 (UDI), §12.1–§12.2 (scope and control of labelling) |
| NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024 | S.I. No. 42 of 2024 | 16 October 2024 | Regulation 19 (product identification), Regulation 23 (registration number) |
3. Expert insights
Insight one: the rules layer says may apply, the GMP layer says must have — the two do not conflict, but their strength differs. The labelling rules use the wording The Use of … may apply for symbols, UDI, QR codes and electronic labelling; GMP §12.6 states that Devices must have a UDI. Accordingly, electronic labelling and QR codes are optional tools, while UDI is a mandatory element. The rigour applied in dossier review and on-site inspection differs accordingly. In dossier review the reviewer checks whether the label artwork is consistent and complete; in inspection the auditor checks whether the quality system actually produces and controls the UDI, which is a heavier test and the reason to embed UDI in the DMR and DHR rather than only in the artwork file.
Insight two: product-specific identification covers seven forms, from which a company may select one or combine several. Batch number, lot number, batch code, lot code, serial number, control number, version number — the product-specific identification is a set of seven selectable forms. For software devices, the version number is expressly listed as one option, which matches software identification practice. Selecting the appropriate form is a design decision: a high-risk implant may justify serial numbers, while a simple consumable may use a batch number. Whatever the choice, the same form must appear on all packaging components so that traceability chains link up.
Insight three: the fallback rule for small packages is to place the details on the primary packaging. Where the product identification details cannot be shown on all packaging components for reasons of size, the details should be shown on the primary packaging. This differs from the relief logic of Regulation 23(2) for registration numbers — product identification cannot be omitted at any packaging level; it can only be concentrated on the smallest package. The distinction is easy to miss: a team that correctly relies on 23(2) to keep the registration number off the primary pack may wrongly conclude the same for product identification, and that error is exactly what market surveillance looks for.
Insight four: GMP brings electronic displays within the scope of labelling. §12.1 provides that labelling covers device labels, control labels, packaging labels, instructions for use, maintenance manuals, and electronic displays that provide directions or warnings. Consequently, on-screen prompts must be brought under labelling control and change management, with the same discipline as printed artwork: versioned specifications, review records and controlled change. A firmware update that alters a safety warning is a label change, and should pass through the same approval route as a printed artwork revision.
Insight five: Nigeria currently has no standalone UDI database provisions. In the official texts verified for this review, no dedicated provisions on a Nigerian UDI database, issuing agency designation or data submission were found. UDI implementation therefore follows GMP §12.6 and the labelling rules; the specific coding scheme and whether reporting to the Agency is required is a practical estimate and must be confirmed case by case. Companies should not copy the UDI implementation model of another jurisdiction wholesale, but should document their chosen issuing agency and coding structure and confirm acceptance with NAFDAC through their local representative before tooling up.
4. Practical recommendations
- Treat UDI as a mandatory element in packaging design and record it in the DMR and DHR.
- Use QR codes and electronic labelling as supplementary means, while retaining paper readability.
- Concentrate product identification on the primary packaging for small-size packages rather than omitting it.
- Bring electronic display content into the labelling SOP and change management.
- Confirm the UDI coding rules and any reporting requirement with the Agency case by case in writing (practical estimate).
The recurring theme is that the mandatory-versus-optional boundary runs through UDI, not through electronic means generally. Budget and project plans should reflect that boundary so that the UDI workstream is never deprioritised in favour of the more visually impressive QR code workstream.
5. Verification checklist
- □ The device carries a UDI indicated on the packaging (GMP §12.6).
- □ Product-specific identification (batch number, serial number, version number, etc.) is shown on all packaging components, or concentrated on the primary packaging under the fallback rule.
- □ QR codes and electronic labels, where used, are consistent with the printed label information.
- □ Electronic display content is under labelling control and change management.
- □ The UDI coding rules and reporting requirements have been confirmed case by case with the Agency (practical estimate).
- □ Label changes have followed the notification or approval procedure of Regulation 6 of the Regulations.
Regulatory information verified as of 29 October 2026. All content cited above was checked against the labelling rules (product identification provision), the GMP guideline (DER-GDL-025-00 §12.1, §12.6) and the Regulations (S.I. No. 42 of 2024, Regulations 19 and 23) as published on the NAFDAC website; no dedicated provisions on UDI coding and reporting were located in the official texts, and the matter is handled as a practical estimate.
GRZAN supports manufacturers entering the Nigerian market with registration documentation and conformity files, including classification determination, registration pathway selection, technical documentation to the IMDRF ToC, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal. Local resources in Nigeria cover licensed import entities and authorised representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Contact: hito.lin@grzan.cn; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us